PRIMARY OBJECTIVE:~I. To evaluate the efficacy of Y90 radioembolization as a 2nd or 3rd line therapeutic option in conjunction with systemic therapy by assessing progression free survival (PFS).~SECONDARY OBJECTIVES:~I. To evaluate the safety of Y90 radioembolization as a 2nd or 3rd line therapeutic option in conjunction with systemic therapy by evaluating treatment related toxicities and identifying baseline predictors of treatment related toxicity.~II. To evaluate the impact of tumor biology i.e. triple negative breast cancer (TNBC) versus (vs.) non-TNBC on PFS and toxicity.~III. To evaluate quality of life (QOL) changes in patients receiving Y90 versus others.~IV. To evaluate the survival (OS) benefit of addition of Y90 radioembolization to systemic therapy.~V. To evaluate compare inflammatory changes in the in the targeted tumors before and after Y90 radioembolization for identification of potential synergistic immunotherapy pathways.~VI. To identify genetic biomarkers of treatment response to Y90 radioembolization.~VII. Evaluation of efficacy and accuracy of hepatobiliary iminodiacetic acid (HIDA) scan as a tool to objectively quantify baseline and post treatment hepatic dysfunction.~VIII. Evaluating timing of Y90 relative to lines of therapies already utilized and disease course.~OUTLINE: Patients are randomized to 1 of 2 arms.~ARM I: Patients receive systemic therapy. Beginning 1-6 weeks after starting systemic therapy, patients also undergo Y90 radioembolization.~ARM II: Patients receive systemic therapy.~After completion of study treatment, patients are followed up at 4-8 weeks, and then every 12-16 weeks for 2 years.
This phase II trial studies the effects of radioembolization with yttrium Y-90 works as a 2nd or 3rd line therapy for treating patients with breast cancer that has spread to the liver (metastatic to the liver). Yttrium Y-90 radioembolization is a therapy that injects radioactive particles directly into an artery that feeds liver tumors to cut off their blood supply.